相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Dihydroergotamine: role in the treatment of migraine
Markus Schuerks
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
Inpatient Treatment of Status Migraine With Dihydroergotamine in Children and Adolescents
Marielle A. Kabbouche et al.
HEADACHE (2009)
Reduced Adverse Event Profile of Orally Inhaled DHE (MAP0004) vs IV DHE: Potential Mechanism
Robert O. Cook et al.
HEADACHE (2009)
Migraine and cardiovascular disease: systematic review and meta-analysis
Markus Schuerks et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward
P. C. Tfelt-Hansen et al.
CEPHALALGIA (2008)
Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics
Stephen B. Shrewsbury et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Safety and pharmacokinetics of dihydroergotamine mesylate administered via a novel (Tempo™) Inhaler
Stephen B. Shrewsbury et al.
HEADACHE (2008)
A pharmacogenomic evaluation of migraine therapy
Matthew P. Johnson et al.
EXPERT OPINION ON PHARMACOTHERAPY (2007)
Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine
Joel R. Saper et al.
HEADACHE (2006)
Patterns of use of triptans and reasons for switching them in a tertiary care migraine population
FD Sheftell et al.
HEADACHE (2004)
Ergotamine and dihydroergotamine: History, pharmacology, and efficacy
SD Silberstein et al.
HEADACHE (2003)
Practical approaches to migraine management
S Diamond et al.
CNS DRUGS (2002)
Prevalence and burden of migraine in the United States: Data from the American Migraine Study II
RB Lipton et al.
HEADACHE (2001)
Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review) - Report of the Quality Standards Subcommittee of the American Academy of Neurology
SD Silberstein
NEUROLOGY (2000)